Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$1.27 - $2.28 $7,029 - $12,619
-5,535 Reduced 9.06%
55,554 $71,000
Q2 2023

Aug 14, 2023

BUY
$1.44 - $2.19 $40,968 - $62,305
28,450 Added 87.17%
61,089 $105,000
Q1 2023

May 15, 2023

SELL
$1.17 - $2.7 $14,677 - $33,871
-12,545 Reduced 27.76%
32,639 $59,000
Q4 2022

Feb 14, 2023

BUY
$2.38 - $3.55 $30,566 - $45,592
12,843 Added 39.71%
45,184 $120,000
Q3 2022

Nov 14, 2022

BUY
$3.14 - $4.87 $737 - $1,144
235 Added 0.73%
32,341 $107,000
Q2 2022

Aug 12, 2022

BUY
$3.03 - $5.32 $50,410 - $88,508
16,637 Added 107.55%
32,106 $117,000
Q1 2022

May 16, 2022

SELL
$4.66 - $7.66 $4,305 - $7,077
-924 Reduced 5.64%
15,469 $79,000
Q4 2021

Feb 14, 2022

BUY
$6.82 - $17.8 $111,800 - $291,795
16,393 New
16,393 $125,000

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $206M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.